Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16603267 | 0.90 | MAOA (0.35) | MAOAMAOBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16603167 | 0.90 | MAOA (0.35) | MAOAMAOBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16603132 | 0.83 | MAOA (0.40) | MAOAMAOBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17545265 | 0.82 | NPC1 (0.33) | MAOAMAOBKMT2A | |
| SCHEMBL16627996 | 0.82 | NPC1 (0.33) | MAOAMAOBKMT2A | |
| SCHEMBL18059283 | 0.82 | POLB (0.33) | MAOAMAOBALDH1A1HPGD | |
| SCHEMBL16603137 | 0.78 | F2R (0.37) | MAOAMAOBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16603223 | 0.77 | MAOA (0.37) | MAOAMAOBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16603134 | 0.77 | MAOA (0.37) | MAOAMAOBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16603254 | 0.76 | F2R (0.36) | MAOAMAOBERCC5FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160260913-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160141522-A1 | Organic Electroluminescent Materials and Devices | UNIVERSAL DISPLAY CORPORATION | 2016-05-19 | — | — | US | disclosed |
| US-20160093816-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160049597-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION | 2016-02-18 | — | — | US | disclosed |
| US-20160049599-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2016-02-18 | — | — | US | disclosed |
| US-20150090981-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160049599-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | SRSF6, SRSF1, DBF4 | MAOA 2032/4885MAOB 1978/4885MEN1 3738/4885 |
| US-20160141522-A1 | Organic Electroluminescent Materials and Devices | EED, ICOSLG, OCIAD1 | MAOA 482/4885MAOB 675/4885MEN1 3615/4885 |
| US-20160093816-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | ACSL3, LUC7L2, L3MBTL3 | MAOA 840/4885MAOB 444/4885MEN1 2874/4885 |
| US-20160260913-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | EML4, TYR, L1CAM | MAOA 650/4885MAOB 257/4885MEN1 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.